Rahlfs Capital’s AbbVie ABBV Stock Holding History

Rahlfs Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.48M	Sell	5,899 -500	-8%	-$108K	1.09%	27
2026 Q1	$1.39M	Sell	6,399 -550	-8%	-$122K	1.02%	32
2025 Q4	$1.59M	Sell	6,949 -63	-0.9%	-$14.4K	1.23%	25
2025 Q3	$1.62M	Hold	7,012	–	–	1.28%	23
2025 Q2	$1.3M	Sell	7,012 -500	-7%	-$92.9K	1.19%	25
2025 Q1	$1.57M	Hold	7,512	–	–	1.58%	19
2024 Q4	$1.33M	Buy	+7,512	New	+$1.38M	1.32%	21

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rahlfs Capital's ABBV Position: Q2 2026 in Review

Rahlfs Capital reduced its AbbVie (ABBV) stake by 7.8% in Q2 2026, selling an estimated $108K and leaving 5,899 shares worth $1.48M. The position accounts for 1.09% of the portfolio, ranked #27.

Rahlfs Capital first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.62M in Q3 2025. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Rahlfs Capital held 5,899 shares of AbbVie worth $1.48M as of Q2 2026.
Rahlfs Capital sold 500 AbbVie shares in Q2 2026, an estimated $108K.
AbbVie made up 1.09% of Rahlfs Capital's portfolio in Q2 2026, its #27 holding.
Rahlfs Capital first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
Rahlfs Capital's AbbVie position peaked at $1.62M in Q3 2025.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Rahlfs Capital's 13F filing for Q2 2026, filed 28 Jul 2026.